300529 健帆生物
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入560,6242.33%2,011,8182,677,3211,922,3482,491,439
减:营业总成本307,801-7.02%1,338,5321,711,4111,420,6421,550,045
    其中:营业成本127,54120.85%428,505514,608389,456440,106
               财务费用8,097-26.06%41,64432,444(33,896)(17,820)
               资产减值损失(7,132)-1,904.42%(63,878)(10,844)(28,182)(6,512)
公允价值变动收益9,489-25.96%111,023--(15)
投资收益82332.89%53,47642,090--10,524
    其中:对联营企业和合营企业的投资收益------------
营业利润261,21610.45%690,7861,045,366543,8191,029,455
利润总额260,01515.50%660,1271,006,964521,0201,016,808
减:所得税费用39,3676.53%128,456192,77895,297135,863
净利润220,64817.26%531,671814,186425,723880,945
减:非控股权益135-122.24%(1,150)(6,009)(10,769)(8,619)
股东净利润220,51316.81%532,821820,195436,492889,564

市场价值指针
每股收益 (元) *0.28021.74%0.6901.0500.5501.120
每股派息 (元) *----0.5200.8000.4000.670
每股净资产 (元) *4.4844.92%4.1984.0263.7504.278
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容